医疗技术公司TransMedics Group Inc.(TMDX)在2024年10月29日盘中大跌,股价一度下挫28.60%,报收于90.20美元。此前公司公布的2024年第三季度财报数据远逊市场预期,引发投资者对其未来增长前景的担忧。
据财报显示,TransMedics Group第三季度营收为1.088亿美元,低于分析师平均预期的1.15亿美元。净利润仅为每股12美分,也未能达到预期的每股29美分。尽管公司维持了全年营收指引在4.25亿至4.45亿美元之间,但市场显然对其业绩增长能力表示失望。
TransMedics Group是一家从事医疗器械领域的公司,专门为终末期器官衰竭患者提供移植治疗。本季度业绩疲软暴露出公司在某些领域可能面临增长瓶颈,无法继续保持之前的高速增长势头。股价重挫反映出投资者对公司前景的担忧情绪。分析师纷纷下调了对公司的盈利预测和目标价。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.